查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840834

獸用抗感染藥感染疾病市場依產品類型、給藥途徑、動物類型、通路和應用分類－全球預測，2025-2032年

Veterinary Anti-infectives Market by Product Type, Route Of Administration, Animal Type, Distribution Channel, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，獸用感染疾病市場規模將成長 109 億美元，複合年成長率為 12.38%。

關鍵市場統計數據
基準年 2024 42.8億美元
預計年份：2025年 48.1億美元
預測年份 2032 109億美元
複合年成長率 (%) 12.38%

本文簡要概述了不斷發展的獸用抗感染疾病領域，闡述了影響該領域策略的臨床需求、管理壓力和商業性因素。

獸用感染疾病物產業正處於曲折點，科學進步、動物健康優先事項的轉變以及不斷變化的監管和貿易環境正在改變產品的研發、分銷和使用方式。本導論簡要說明了影響伴侶動物、牲畜、家禽和水產養殖中抗生素、抗真菌藥物和抗寄生蟲藥物治療的關鍵因素。它重點關注臨床需求、管理要求和商業性現實之間的相互作用，為深入分析市場動態和戰略意義奠定了基礎。

隨著動物健康系統不斷應對抗菌素抗藥性、生物安全標準提高以及供應鏈變化等壓力，相關人員必須權衡短期營運挑戰與長期投資決策。將臨床療效、安全性和合理使用相結合的綜合方法日益成為產品定位的核心。此外，從數位診斷到精準給藥系統等技術賦能手段正在改變新療法和現有治療方法的價值提案。透過重點闡述這些因素，讀者將理解為何跨職能協作、數據主導的決策以及敏捷的商業化策略對於在快速變化的環境中維持成長並確保治療相關性至關重要。

確定影響獸用感染疾病物轉型的關鍵促進因素，包括診斷、管理、供應彈性以及數位分銷動態

在科學創新、監管趨嚴和相關人員期望轉變的推動下，獸用感染疾病物領域正經歷變革性的轉變。診斷技術的進步加速了從經驗性治療到標靶治療的轉變，使獸醫能夠更精準地選擇藥物，同時減少不必要的用藥。同時，抗菌藥物管理也受到越來越多的關注，監管機構和採購方要求提供更清晰的證據，以證明藥物的合理使用和風險緩解策略，這正在影響處方決策和行為。

同時，供應鏈正經歷一段重新調整期。優先考慮地域多元化、品質保證和供應商透明度的籌資策略正逐漸成為標準做法。數位化平台和遠端醫療也在擴大獸醫諮詢和治療管理的覆蓋範圍，創造了新的通路，同時也引發了關於有效監管的疑問。對新型治療方法和製劑技術的公共和私人投資持續成長，但對健全的上市後監測和生命週期管理的需求也日益增加。總而言之，這些變化迫使製造商重新思考其產品開發重點、監管互動和商業模式，以在既重視療效又重視負責任管理的環境中保持競爭力並遵守相關法規。

分析關稅變化和貿易政策轉變如何影響整個價值鏈的供應鏈決策、定價策略和風險緩解措施。

關稅和貿易政策的實施為獸用感染疾病的商業環境帶來了新的複雜性。關稅調整可能會影響生產佈局、採購決策和定價策略，促使生產商和經銷商重新評估其全球供應鏈。為此，許多公司正在考慮近岸外包、雙重採購和庫存最佳化等措施，以減輕關稅相關成本波動的影響，並維持關鍵治療藥物的持續供應。

這些政策主導的轉變將與現有的監管和市場壓力相互作用，影響製造外包、庫存分配和市場通路結構的決策。擁有垂直整合供應鏈和多元化生產基地的公司通常更有能力吸收不斷上漲的關稅成本，而無需將全部負擔轉嫁給最終客戶。相反，依賴單一來源進口或高銷售量、低利潤產品線的公司可能面臨利潤率壓縮，需要進行策略性重新定價、重新談判供應商條款或調整通路獎勵。在這些情況下，情境規劃和關稅影響建模對於希望在保障基本抗感染疾病治療藥物供應的同時，維持商業性可行性並協調相關人員預期的領導者而言，至關重要。

基於產品類型、給藥途徑、動物類別、分銷管道和應用場景等深度主導洞察，產品策略得以建構。

細分市場層面的洞察揭示了不同產品類型、給藥途徑、動物類別、分銷管道和應用領域之間的差異化動態，這些因素共同影響研發重點和市場推廣策略。就產品類型而言，抗生素仍然是核心，但它們的內部發展軌跡各不相同。Aminoglycosides、BETA-內醯胺類、Fluoroquinolones、大環內酯類、磺胺類藥物和四環黴素均面臨管理和監管方面的考量，這些考慮會影響標籤、停藥期和使用指南。抗真菌藥物物（分為Azole和Polyenes）需要精細的製劑策略，以平衡局部和全身給藥的療效和安全性。抗寄生蟲藥物（包括殺蟎劑、驅蟲劑和殺蟲劑）的研發擴大考慮到抗藥性和環境影響，指南研究方向轉向新的化學實體及其在綜合蟲害管理中的應用。

給藥途徑進一步影響藥物的採納和產品開發選擇。注射劑型，例如肌肉注射、靜脈注射和皮下注射，通常優先用於急性護理和住院動物；而口服劑型，例如顆粒劑、粉劑、混懸劑和片劑，則更適合牛管理和伴侶動物護理中的便捷給藥。外用劑型，例如乳膏、浸劑、軟膏和噴霧劑，在皮膚病和體外寄生蟲的治療中發揮至關重要的作用，因為局部作用和快速起效至關重要。水產養殖（魚蝦）需要水穩定性好且環境友善的製劑；伴侶動物（貓狗）優先考慮安全性和易於飼主使用的給藥方式；牲畜（牛、羊、山羊和豬）強調停藥期和群體給藥的實用性；家禽（雞和火雞）則需要將解決方案整合到畜群健康管理通訊協定中。線上藥局、實體藥局、獸醫診所和動物醫院各自面臨不同的監管環境、利潤結構和客戶參與模式。此外，預防用途與治療用途也會影響產品定位、證據要求和相關人員溝通：預防用途需要在監管框架下接受更嚴格的審查，而治療用途則需要可靠的臨床療效數據。

對全球主要地區的監管預期、分銷差異和市場准入考慮進行全面的區域分析

區域動態在塑造美洲、歐洲、中東和非洲以及亞太地區的監管預期、供應鏈設計和商業策略方面發揮關鍵作用。美洲是一個成熟的動物用藥品市場，擁有高標準的監管合規性和完善的分銷網路。這促使製造商更加重視證據生成、標籤差異化和基於價值的契約，以適應採購和動物診療模式。相較之下，歐洲、中東和非洲地區則呈現異質性。歐洲部分地區需要嚴格的監管和藥物安全檢測，而該地區其他市場的監管能力則各不相同，這推動了對適應性打入市場策略的需求日益成長。

亞太地區市場多元化，既有成熟市場，也有快速成長市場。特別是畜牧業集約化和水產養殖業的擴張，大大推動了對高效抗感染疾病解決方案的需求。然而，這種成長也帶來了對品質保證和監測的迫切需求，以降低抗藥性風險。在任何地區，貿易政策、進口法規以及當地強制性的生產和註冊要求的變化都可能對時間表和市場准入選擇產生重大影響。因此，區域策略必須在遵循全球標準化的同時，兼顧區域特定法規、區域特定證據包，並與獸醫、生產商和經銷商進行符合當地文化的溝通。

分析決定抗感染疾病產品組合領導地位和差異化的競爭定位、創新路徑和夥伴關係模式

獸用感染疾病市場的競爭格局由成熟的製藥公司、專業的動物用藥品公司和新興的生物技術公司組成，它們在研發、生產和商業化方面都採取了獨特的策略。老字型大小企業利用其廣泛的產品組合、豐富的監管經驗和全球分銷網路來維持市場地位，而規模較小的公司則往往憑藉針對特定適應症、特殊配方和更快的研發週期來競爭。生物技術參與企業和委外研發機構正透過新型活性成分、標靶給藥系統和替代配方等創新手段，為傳統化學製劑帶來顛覆性挑戰。

夥伴關係和策略聯盟日益普遍，有助於企業擴大規模、取得專有技術並加速註冊流程。投資強大的藥物安全檢測、抗藥性監測和證據生成的公司，更有能力滿足不斷變化的監管要求，並以可靠的數據支持其藥物管理理念。同時，在生產品質、供應鏈風險管理和數位化互動（例如遠端醫療產品支援和數據驅動的給藥工具）方面的內部能力，也是市場領導脫穎而出的關鍵。總而言之，競爭格局有利於那些將科學嚴謹性與營運韌性相結合，並提供針對特定客戶群量身定做的、提案的價值主張的企業。

為產業領導者提供切實可行的優先建議，以增強供應鏈韌性、證據產生、管理協調和商業性差異化。

產業領導者應採取一系列切實可行的措施，在短期營運韌性和長期策略優勢之間取得平衡。首先，透過多元化採購、雙通路籌資策略以及嚴格的供應商品質審核來增強供應鏈韌性，從而降低關稅和貿易中斷的影響。其次，將診斷應用案例融入產品開發和商業性定位，以支持標靶治療、減少不當使用，並強化能夠引起監管機構和採購方共鳴的藥物管理主張。第三，投資於能夠證明長期安全性和價值的證據生成，不僅包括註冊試驗，還應包括真實世界療效試驗、抗藥性監測和藥物安全檢測。

此外，企業領導者應探索配方和給藥方式的創新，以提高用藥依從性並減少環境暴露，尤其是在水產養殖和集約化畜牧養殖環境中。從遠端醫療處方支援到行動劑量計算器等數位化工具，可以提高用藥依從性，並為教育和上市後資料收集提供管道。最後，企業應採用適應性定價和合約策略，既要考慮當地的支付能力限制，也要保留利潤空間用於研發再投資。將嚴謹的營運、臨床證據和以客戶為中心的商業模式結合，可以幫助企業成功應對監管預期並保持競爭優勢。

我們對多來源調查方法進行了透明的解釋，該方法結合了專家意見、監管審查和情境分析，從而確保得出可靠且檢驗的結論。

本分析的調查方法結合了專家定性訪談、二手文獻綜述以及對監管指南和公開臨床證據的結構化綜合分析。主要資訊來源包括與獸醫、監管專家、生產和供應鏈高管以及分銷合作夥伴的諮詢，以了解不同物種和管道的實踐和決策標準。二級資訊來源包括關於抗菌素抗藥性的同行評審文獻、監管指南文件和行業出版物，以確認其與公認的臨床和政策框架的一致性。

我們的分析包括對定性輸入資料進行主題編碼，以考慮市場細分和評估競爭情況；同時，監管和臨床文件使我們能夠解讀藥品管理和安全方面的限制。情境分析探討了貿易和關稅變化對供應鏈和定價的影響，尤其關注能夠維持藥品可及性和品質的途徑。在整個過程中，我們透過多種資訊來源檢驗了我們的發現，力求清晰地揭示不確定性，並確保我們的建議是基於可靠的證據和充分的判斷。

最後總結強調了製定與管理、供應鏈韌性、證據產生和商業性模式一致的整合策略的必要性。

總之，獸用感染疾病物市場正受到科學、監管和商業性力量共同作用的重塑，需要產業相關人員採取綜合應對措施。抗菌藥物管理指令和診斷技術的進步正推動產品研發朝著精準用藥和實證醫學的方向發展，而政策變化和關稅則促使企業建立更具韌性的供應鏈。產品類型、給藥途徑、動物種類、配銷通路和使用場景的碎片化表明，一刀切的策略已不再適用，而是需要根據物種特異性需求、當地監管差異和管道動態制定量身定做的方案。

具有前瞻性的企業將優先投資於支持負責任使用、展現臨床和經濟價值以及提升營運靈活性的專案。透過將研發重點與管理期望相契合、增強供應鏈韌性並利用數位化和診斷技術，企業既能滿足當前的市場需求，又能建立永續的競爭優勢。未來面臨的挑戰在於，科學、監管和商業部門如何通力合作，將研究成果轉化為可執行的方案，在確保有效治療方法可及性的同時，保護動物和公眾健康。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 抗菌素抗藥性的日益增強正在推動對新型獸用抗生素和替代療法的需求。
  • 精準畜牧業的發展推動了標靶抗感染劑傳遞技術的發展。
  • 更嚴格的抗生素使用監管推動了噬菌體療法的普及。
  • 伴侶動物醫療保健成本飆升推動物種特異性感染疾病的創新
  • 獸用疫苗和免疫調節劑的廣泛使用減少了對抗生素的依賴。
  • 擴大海外獸用生技藥品生產可以提高供應鏈的韌性。
  • 在診所中整合抗菌藥物管理計劃和即時診斷工具
  • 開發長效注射型抗感染製劑以提高治療順從性
  • 投資者對利用微生物組調節療法預防牲畜疾病的興趣日益濃厚
  • 引入數位監測平台，追蹤農場抗生素使用和抗藥性趨勢

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的動物感染疾病物市場

  • 抗生素
    • Aminoglycosides
    • BETA-內醯胺類
    • Fluoroquinolones
    • 大環內酯類
    • 磺胺類藥物
    • 四環黴素
  • 抗真菌藥物
    • Azole
    • Polyenes
  • 抗寄生蟲藥物
    • 殺蟎劑
    • 驅蟲藥
    • 殺蟲劑

9. 依給藥途徑分類的動物感染疾病物市場

  • 注射
    • 肌肉內注射
    • 靜脈
    • 皮下
  • 口服
    • 顆粒
    • 粉末
    • 暫停
    • 藥片
  • 外用藥物
    • 奶油
    • 沾
    • 軟膏
    • 噴

第10章 依動物類型分類的動物感染疾病物市場

  • 水產養殖
    • 魚
    • 蝦
  • 伴侶動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 山羊
    • 羊
    • 豬
  • 家禽
    • 雞
    • 火雞

第11章：按分銷管道分類的動物感染疾病物市場

  • 網路藥房
  • 零售藥房
  • 獸醫診所
  • 獸醫診所

第12章：按應用分類的動物感染疾病物市場

  • 預防
  • 治療

第13章：各地區動物感染疾病物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按類別分類的動物感染疾病物市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國動物感染疾病物市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Merck & Co., Inc.
    • CH Boehringer Sohn AG & Co. KG
    • Intas Pharmaceuticals Ltd.
    • Ceva Sante Animale SA
    • Vetoquinol SA
    • Eco Animal Health Group PLC
    • Virbac SA
    • Sequent Scientific Ltd.
Product Code: MRR-2214614768CF

The Veterinary Anti-infectives Market is projected to grow by USD 10.90 billion at a CAGR of 12.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.28 billion
Estimated Year [2025] USD 4.81 billion
Forecast Year [2032] USD 10.90 billion
CAGR (%) 12.38%

Concise orientation to the evolving veterinary anti-infectives sector setting context on clinical needs, stewardship pressures, and commercial imperatives shaping strategy

The veterinary anti-infectives sector is at an inflection point where scientific advances, shifting animal health priorities, and evolving regulatory and trade environments are reshaping how products are developed, distributed, and used. This introduction provides a concise orientation to the core drivers affecting antibiotic, antifungal, and antiparasitic therapies across companion animals, livestock, poultry, and aquaculture. It highlights the interplay between clinical need, stewardship imperatives, and commercial realities, setting the stage for deeper analysis of market dynamics and strategic implications.

As animal health systems adapt to pressures such as antimicrobial resistance concerns, heightened biosecurity standards, and changes in supply chains, stakeholders must reconcile short-term operational challenges with long-term investment decisions. Integrated approaches that combine clinical efficacy, safety, and responsible use are increasingly central to product positioning. Moreover, technological enablers-ranging from digital diagnostics to precision delivery systems-are altering the value proposition for new and existing therapies. Framing these forces up front ensures readers appreciate why cross-functional alignment, data-driven decision-making, and agile commercialization strategies are essential for sustaining growth and ensuring therapeutic relevance in a rapidly changing landscape.

Identification of the major transformative forces reshaping veterinary anti-infectives including diagnostics, stewardship, supply resilience, and digital distribution dynamics

The landscape for veterinary anti-infectives is experiencing transformative shifts driven by scientific innovation, regulatory tightening, and changes in stakeholder expectations. Advances in diagnostic capabilities are accelerating the move from empirical treatment toward targeted therapy, enabling veterinarians to select agents with greater precision while reducing unnecessary use. In parallel, there is intensified scrutiny on antimicrobial stewardship, with regulators and purchasers demanding clearer evidence of appropriate use and risk mitigation strategies, which in turn influences formulary decisions and prescribing behavior.

Concurrently, the supply chain is undergoing recalibration. Sourcing strategies that prioritize geographic diversity, quality assurance, and supplier transparency are becoming standard practices. Digital platforms and telemedicine are also expanding access to veterinary consultation and therapy management, creating new channels for distribution while raising questions about appropriate oversight. Private and public investment in novel modalities and formulation technologies continues to grow, but so does the need for robust post-market surveillance and lifecycle management. Collectively, these shifts are prompting manufacturers to rethink product development priorities, regulatory engagement, and commercial models to remain relevant and compliant in an environment that prizes both efficacy and responsible stewardship.

Analysis of how tariff changes and trade policy shifts are influencing supply chain decisions, pricing strategies, and risk mitigation approaches across the value chain

The introduction of tariffs and trade policy changes has added a new layer of complexity to the operational environment for veterinary anti-infectives. Tariff adjustments can influence manufacturing footprints, sourcing decisions, and pricing strategies, prompting manufacturers and distributors to reassess their global supply chains. In response, many organizations are examining nearshoring, dual-sourcing, and inventory optimization measures to mitigate exposure to tariff-related cost volatility and to preserve supply continuity for critical therapies.

These policy-driven shifts interact with existing regulatory and market pressures, affecting decisions related to contract manufacturing, inventory allocation, and route-to-market structuring. Companies with vertically integrated supply chains or diversified production locations are generally better positioned to absorb incremental tariff costs without passing the full burden onto end customers. Conversely, firms reliant on single-source imports or high-volume, low-margin product lines may face margin compression that requires strategic repricing, renegotiation of supplier terms, or adjusted channel incentives. In this context, scenario planning and tariff-impact modelling become essential tools for leaders seeking to protect access to essential anti-infective treatments while sustaining commercial viability and aligning stakeholder expectations.

Deep segmentation-driven insights across product types, administration routes, animal classes, distribution channels, and application contexts shaping product strategies

Segment-level insights reveal differentiated dynamics across product types, routes of administration, animal classes, distribution channels, and applications that together shape development priorities and go-to-market strategies. Within product type, antibiotics remain central but their internal trajectories diverge: aminoglycosides, beta-lactams, fluoroquinolones, macrolides, sulfonamides, and tetracyclines each face distinct stewardship and regulatory considerations that influence label claims, withdrawal periods, and usage guidelines. Antifungals, segmented into azoles and polyenes, demand nuanced formulation strategies to balance efficacy with safety in both topical and systemic applications. Antiparasitics-spanning acaricides, anthelmintics, and insecticides-are increasingly developed with resistance management and environmental impact in mind, guiding research toward novel chemistries and integrated pest management compatibility.

Route of administration further affects adoption and product development choices. Injectable options, whether intramuscular, intravenous, or subcutaneous, are often prioritized for acute care and hospitalized animals, while oral formulations-pellets, powders, suspensions, and tablets-are tailored for ease of dosing in herd management and companion care. Topical formats such as creams, dips, ointments, and sprays play a pivotal role in dermatological and ectoparasite management where localized exposure and rapid action are critical. Animal type segmentation differentiates clinical pathways and commercial approaches; aquaculture (fish and shrimp) requires water-stable and environmentally considerate chemistries, companion animals (cats and dogs) prioritize safety and owner-friendly dosing, livestock (cattle, goats, sheep, swine) emphasize withdrawal times and mass-administration practicality, and poultry (chicken and turkey) demand solutions that integrate into flock health protocols. Distribution channels shape access and commercial interaction: online pharmacies, retail pharmacies, veterinary clinics, and veterinary hospitals each present different regulatory touchpoints, margin structures, and customer engagement models. Lastly, the application lens-prophylactic versus therapeutic-drives product positioning, evidence requirements, and stakeholder communications, with prophylactic uses prompting additional scrutiny under stewardship frameworks and therapeutic indications necessitating robust clinical efficacy data.

Comprehensive regional analysis of regulatory expectations, distribution nuances, and market access considerations across major global territories

Regional dynamics play a pivotal role in shaping regulatory expectations, supply chain design, and commercial tactics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas present a mature veterinary market with high standards for regulatory compliance and established distribution networks; manufacturers therefore emphasize evidence generation, label differentiation, and value-based contracting to align with procurement and veterinary practice patterns. In contrast, the Europe, Middle East & Africa region is heterogeneous: parts of Europe demand rigorous stewardship and pharmacovigilance, while other markets in the broader region present variable regulatory capacity and growing demand that calls for adaptable market-entry strategies.

Asia-Pacific features diverse market maturities and rapid growth pockets, especially where livestock intensification and aquaculture expansion amplify demand for effective anti-infective solutions; however, this growth is accompanied by a pressing need for quality assurance and monitoring to mitigate resistance risks. Across all regions, trade policy variations, import controls, and locally mandated manufacturing or registration requirements can materially affect timelines and go-to-market choices. Consequently, regional strategies must balance global standardization with localized regulatory navigation, tailored evidence packages, and culturally informed engagement models with veterinarians, producers, and distributors.

Examination of competitive positioning, innovation pathways, and partnership models that determine leadership and differentiation in anti-infective portfolios

Competitive dynamics in veterinary anti-infectives are shaped by a mix of established pharmaceutical companies, specialized animal health players, and emerging biotech innovators, each pursuing distinct strategies across research, manufacturing, and commercialization. Established firms leverage broad portfolios, regulatory experience, and global distribution networks to maintain market presence, while smaller and mid-sized companies often compete on niche indications, specialized formulations, or faster development cycles. Biotech entrants and contract research organizations contribute innovation in novel active ingredients, targeted delivery systems, and alternative modalities that may disrupt traditional chemistries.

Partnerships and strategic alliances are increasingly common, enabling scale-up, access to proprietary technologies, or acceleration of registration pathways. Companies that invest in robust pharmacovigilance, resistance monitoring, and evidence generation are better equipped to meet evolving regulatory expectations and to support stewardship narratives with credible data. At the same time, internal capabilities in manufacturing quality, supply-chain risk management, and digital engagement-such as telehealth-enabled product support or data-driven dosing tools-differentiate market leaders. Overall, the competitive landscape rewards organizations that combine scientific rigor with operational resilience and compelling value propositions tailored to customer segments.

Practical and prioritized recommendations for industry leaders to strengthen supply resilience, evidence generation, stewardship alignment, and commercial differentiation

Industry leaders should pursue a set of actionable steps that balance near-term operational resilience with long-term strategic advantage. First, fortify supply-chain resilience through diversified sourcing, dual-sourcing strategies, and rigorous supplier quality audits to mitigate tariff and trade disruptions. Second, integrate diagnostic-enabled use cases into product development and commercial positioning to support targeted therapy, reduce inappropriate usage, and strengthen stewardship claims that resonate with regulators and purchasers. Third, invest in evidence generation that goes beyond registration trials to include real-world effectiveness studies, resistance surveillance, and pharmacovigilance that collectively substantiate long-term safety and value.

Moreover, leaders should explore formulation and delivery innovations that improve dosing compliance and reduce environmental exposure, particularly for aquaculture and intensive livestock settings. Digital tools-ranging from telemedicine-enabled prescribing support to mobile dosing calculators-can enhance adherence and provide channels for education and post-market data collection. Finally, adopt adaptive pricing and contracting approaches that recognize regional affordability constraints while preserving margins for reinvestment in R&D. By combining operational rigor, clinical evidence, and customer-centric commercial models, companies can better navigate regulatory expectations and sustain competitive differentiation.

Transparent explanation of the multi-source research methodology combining expert input, regulatory review, and scenario analysis to ensure robust, validated conclusions

The research methodology underpinning this analysis combines qualitative expert interviews, secondary literature review, and structured synthesis of regulatory guidance and public-domain clinical evidence. Primary inputs included consultations with veterinarians, regulatory specialists, manufacturing and supply-chain executives, and distribution partners to capture operational realities and decision criteria across species and channels. Secondary sources encompassed peer-reviewed literature on antimicrobial resistance, regulatory agency guidance documents, and industry publications to ensure alignment with accepted clinical and policy frameworks.

Analysis followed a triangulated approach: thematic coding of qualitative inputs informed segmentation insights and competitive assessments, while regulatory and clinical documents anchored interpretations of stewardship and safety constraints. Scenario analysis was employed to explore the operational implications of trade and tariff changes on supply chains and pricing dynamics, with particular attention to pathways that preserve access and quality. Throughout the process, efforts were made to validate findings against multiple sources and to surface uncertainties explicitly, ensuring that recommendations are grounded in robust evidence and informed judgment.

Final synthesis emphasizing the need for integrated strategies across stewardship, supply resilience, evidence generation, and tailored commercial approaches

In conclusion, the veterinary anti-infectives landscape is being reshaped by a convergence of scientific, regulatory, and commercial forces that require integrated responses from industry stakeholders. Antimicrobial stewardship imperatives and diagnostic advances are redirecting product development toward precision use and robust evidence generation, while policy shifts and tariffs are prompting more resilient supply-chain designs. Segmentation across product types, routes of administration, animal types, distribution channels, and application contexts underscores that one-size-fits-all strategies are no longer sufficient; rather, tailored approaches that address species-specific needs, regional regulatory nuance, and channel-specific dynamics are essential.

Forward-looking organizations will prioritize investments that support responsible use, demonstrate clinical and economic value, and enhance operational flexibility. By aligning R&D priorities with stewardship expectations, strengthening supply-chain resilience, and leveraging digital and diagnostic enablers, companies can both meet immediate market demands and build sustainable competitive advantage. The path forward demands coordination across scientific, regulatory, and commercial functions to translate insights into actionable programs that secure access to effective therapies while safeguarding animal and public health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising antimicrobial resistance driving demand for novel veterinary antibiotics and alternative therapies
  • 5.2. Growth in precision livestock farming boosting targeted anti-infective delivery technologies
  • 5.3. Increasing regulatory scrutiny on antibiotic use fueling adoption of bacteriophage therapies
  • 5.4. Surge in companion animal healthcare spending driving innovation in species-specific anti-infectives
  • 5.5. Widespread adoption of veterinary vaccines and immunomodulators reducing antibiotic reliance
  • 5.6. Expansion of offshore veterinary biologics manufacturing enhancing supply chain resilience
  • 5.7. Integration of point-of-care diagnostic tools with antibiotic stewardship programs in clinics
  • 5.8. Development of long-acting injectable anti-infective formulations to improve treatment compliance
  • 5.9. Rising investor interest in microbiome modulation therapies for livestock disease prevention
  • 5.10. Implementation of digital monitoring platforms to track antibiotic usage and resistance trends on farms

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Anti-infectives Market, by Product Type

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta Lactams
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Sulfonamides
    • 8.1.6. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Polyenes
  • 8.3. Antiparasitics
    • 8.3.1. Acaricides
    • 8.3.2. Anthelmintics
    • 8.3.3. Insecticides

9. Veterinary Anti-infectives Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Pellets
    • 9.2.2. Powders
    • 9.2.3. Suspensions
    • 9.2.4. Tablets
  • 9.3. Topical
    • 9.3.1. Creams
    • 9.3.2. Dips
    • 9.3.3. Ointments
    • 9.3.4. Sprays

10. Veterinary Anti-infectives Market, by Animal Type

  • 10.1. Aquaculture
    • 10.1.1. Fish
    • 10.1.2. Shrimp
  • 10.2. Companion Animal
    • 10.2.1. Cats
    • 10.2.2. Dogs
  • 10.3. Livestock
    • 10.3.1. Cattle
    • 10.3.2. Goats
    • 10.3.3. Sheep
    • 10.3.4. Swine
  • 10.4. Poultry
    • 10.4.1. Chicken
    • 10.4.2. Turkey

11. Veterinary Anti-infectives Market, by Distribution Channel

  • 11.1. Online Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Clinics
  • 11.4. Veterinary Hospitals

12. Veterinary Anti-infectives Market, by Application

  • 12.1. Prophylactic
  • 12.2. Therapeutic

13. Veterinary Anti-infectives Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Anti-infectives Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Anti-infectives Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Zoetis Inc.
    • 16.3.2. Elanco Animal Health Incorporated
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. C.H. Boehringer Sohn AG & Co. KG
    • 16.3.5. Intas Pharmaceuticals Ltd.
    • 16.3.6. Ceva Sante Animale SA
    • 16.3.7. Vetoquinol SA
    • 16.3.8. Eco Animal Health Group PLC
    • 16.3.9. Virbac SA
    • 16.3.10. Sequent Scientific Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VETERINARY ANTI-INFECTIVES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VETERINARY ANTI-INFECTIVES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY ANTI-INFECTIVES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ACARICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INSECTICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY PELLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHRIMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY GOATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SHEEP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY CHICKEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY TURKEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL VETERINARY ANTI-INFECTIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)

TABLE